Author

D. B. Volkin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 6 Approach:experimental assay· 5 Organism:mouse· 4 Assay:proteomics· 3 Organism:non-human primate· 2 Assay:protein structure· 2 Approach:biophysical modeling· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

S. B. Joshi· 7 shared K. Kaur· 4 shared O. S. Kumru· 4 shared H. Kleanthous· 3 shared J. C. Love· 3 shared N. C. Dalvie· 3 shared S. A. Rodriguez-Aponte· 3 shared S. Bajoria· 3 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

S. B. Joshi

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines

O. Kumru, M. Sanyal, N. Friedland, J. Hickey, R. Joshi, P. Weidenbacher, J. Do, Y.-C. Cheng, P. S. Kim, S. B. Joshi, D. B. Volkin

This study develops and compares an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced in two cell lines, showing similar immunogenicity despite differences in glycoforms.

Vaccine · Oct 1, 2023Peer-reviewedImmunology

Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor binding domain (RBD)

O. S. Kumru, S. Bajoria, K. Kaur, J. M. Hickey, G. Van Slyke, J. Doering, K. Berman, C. Richardson, H. Lien, H. Kleanthous, N. J. Mantis, S. B. Joshi, D. B. Volkin

This paper evaluates the stability and immunogenicity of a SARS-CoV-2 RBD VLP vaccine candidate formulated with different adjuvants and finds that AP and AH adjuvants provide comparable immunogenicity to AV, with AP showing higher neutralizing titers.

bioRxiv · Jul 10, 2023Immunology

Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate

P. Kumar, M. Wang, O. S. Kumru, J. Hickey, J. Sanmiguel, N. Zabaleta, L. H. Vandenberghe, S. B. Joshi, D. B. Volkin

The paper correlates physicochemical properties of an rAAV vaccine candidate with its biological potency, showing links between physical stability, transduction efficiency, and immunogenicity.

bioRxiv · Mar 10, 2023Immunology

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

P. A.- B. Weidenbacher, M. Sanyal, N. Friedland, S. Tang, P. S Arunachalam, M. Hu, O. S. Kumru, M. K. Morris, J. Fontenot, L. Shirreff, J. Do, Y.-C. Cheng, G. Vasudevan, M. B. Feinberg, F. J. Villinger, , P. S. Kim

This paper describes a ferritin-based nanoparticle vaccine, DCFHP-alum, that induces strong, long-lasting neutralizing antibodies against SARS-CoV-2 variants in non-human primates.

bioRxiv · Dec 25, 2022Immunology

Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants

S. A. Rodriguez-Aponte, N. C. Dalvie, T. Y. Wong, R. S. Johnston, C. A. Naranjo, S. Bajoria, O. S. Kumru, K. Kaur, B. P. Russ, K. S. Lee, H. A. Cyphert, M. Barbier, H. D. Rao, M. P. Rajurkar, R. R. Lothe, , J. C. Love

bioRxiv · Sep 14, 2022Bioengineering

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

N. C. Dalvie, L. H. Tostanoski, S. A. Rodriguez-Aponte, K. Kaur, S. Bajoria, O. Kumru, A. J. Martinot, A. Chandrashekar, K. McMahan, N. B. Mercado, J. Yu, A. Chang, V. M. Giffin, F. Nampanya, S. Patel, , D. H. Barouch

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

bioRxiv · Jul 13, 2021 · PreprintImmunology

Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus

N. C. Dalvie, J. R. Brady, L. E. Crowell, M. K. Tracey, A. M. Biedermann, K. Kaur, J. M. Hickey, D. L. Kristensen, A. Bonnyman, S. A. Rodriguez-Aponte, C. A. Whittaker, M. Bok, C. Vega, T. Mukhopadhyay, S. B. Joshi, , J. C. Love

The paper engineers subunit antigens to improve vaccine manufacturing by reducing variants and enabling single-process production of a trivalent rotavirus vaccine.

bioRxiv · Nov 20, 2020Bioengineering